• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    1,088.77 +27.91 (+2.63%)
    Streaming Delayed Price Updated: 11:55 AM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 Next >
    CPI Data Sparks Rally in Biotech Stocks
    Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
    Via MarketBeat
    Topics ETFs Economy
    Exposures Interest Rates
    Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
    Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell... 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
    Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
    From Kirby McInerney LLP
    Via Business Wire
    Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Will the Biotech Sector Shift From Lagger to Leader?
    The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. 
    Via MarketBeat
    Topics ETFs
    Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Announces Investor Conference Presentations
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Reports First Quarter 2024 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
    Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and... 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
    From Kirby McInerney LLP
    Via GlobeNewswire
    REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Law Offices of Frank R. Cruz
    Via Business Wire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
    Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Regeneron Provides Update on Biologics License Application for Odronextamab
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.